West Pharmaceutical Services (WST) is Returning to Sustainable Volume Growth

4 weeks ago 13

Soumya Eswaran

Fri, February 20, 2026 astatine 8:30 AM CST 3 min read

Conestoga Capital Advisors, an plus absorption company, released its fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. In Q4 2025, Conestoga Capital Advisors Mid Cap Strategy returned -5.75% nett of fees compared to the Russell Midcap Growth Index’s -3.70% return. The underperformance was driven by antagonistic banal enactment successful the Technology and Industrials sectors, portion affirmative assemblage allocation effects partially eased underperformance. The Mid Cap Composite returned -4.73% nett of fees for the afloat twelvemonth 2025, trailing the benchmark instrumentality of 8.66%. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Conestoga Capital Advisors highlighted stocks specified arsenic West Pharmaceutical Services, Inc. (NYSE:WST). West Pharmaceutical Services, Inc. (NYSE:WST) designs, manufactures, and sells containment and transportation systems for injectable drugs and healthcare products. On February 19, 2026, West Pharmaceutical Services, Inc. (NYSE:WST) banal closed astatine $243.83 per share. One-month instrumentality of West Pharmaceutical Services, Inc. (NYSE:WST) was 3.03%, and its shares gained 15.61% implicit the past 52 weeks. West Pharmaceutical Services, Inc. (NYSE:WST) has a marketplace capitalization of $17.566 billion.

Conestoga Capital Advisors stated the pursuing regarding West Pharmaceutical Services, Inc. (NYSE:WST) successful its 4th fourth 2025 capitalist letter:

"West Pharmaceutical Services, Inc. (NYSE:WST) manufactures packaging components and transportation systems for injectable drugs and healthcare products. The company’s beardown show was driven by continued momentum successful its High-Value Products segment, peculiarly for GLP-1 obesity and diabetes therapies. Management indicated that erstwhile destocking headwinds person moderated, paving the mode for a instrumentality to sustainable measurement growth. We judge WST remains a captious spouse to the pharmaceutical industry, good positioned to payment from the semipermanent secular trends toward biologic and injectable medicines."

KeyBanc Sees Injectable GLP-1s Driving Ongoing Demand for WST

West Pharmaceutical Services, Inc. (NYSE:WST) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 49 hedge money portfolios held West Pharmaceutical Services, Inc. (NYSE:WST) astatine the extremity of the 3rd quarter, up from 46 successful the erstwhile quarter. While we admit the imaginable of West Pharmaceutical Services, Inc. (NYSE:WST) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article